Inhibrx Biosciences (INBX) Return on Assets (2024 - 2025)
Inhibrx Biosciences' (INBX) quarterly Return on Assets came in at 0.01% in Q4 2025, down 9.0% year-on-year from 0.01% in Q4 2024, and down 8.61% on a QoQ basis from 0.01% in Q3 2025.
Inhibrx Biosciences (INBX) Return on Assets (2024 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 2 years of Return on Assets data on file, last reported at 0.01% in Q4 2025.
- On a quarterly basis, Return on Assets fell 9.0% year-over-year to 0.01% in Q4 2025; TTM through Dec 2025 was 0.01%, a 9.0% decrease from a year earlier, with the FY2025 full-year figure at 0.01%, down 8.0% from the prior year.
- Return on Assets for Q4 2025 stood at 0.01%, down from 0.01% in the prior quarter.
- Over the last five years, Return on Assets for INBX reached as high as 0.08% in Q4 2024 and fell as low as 0.01% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -0.69% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.01% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -0.80% |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 0.00% |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | 0.08% |
| Dec 31, 2024 | 0.08% |
| Sep 30, 2024 | 0.07% |